December 21, 2010

Semprus BioSciences today announced the company has won the Frost & Sullivan 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies for its Semprus Platform.

Semprus BioSciences is a venture-funded biomedical company designing products to give patients and clinicians new tools to eliminate the 56,000 preventable annual U.S. deaths and $11.2 billion cost of infection- and thrombus-related complications* that arise when vascular access products are implanted in the body. The company spun out of the labs of biomedical researcher and Massachusetts Institute of Technology (MIT) Professor Robert Langer in 2007, following its first place finish in MIT’s $100K Entrepreneurship Competition, as well as Oxford University’s Said School’s Entrepreneurial Competition.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that enhances current products and enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology and is supported by the 1,800 analysts and consultants at Frost and Sullivan who cover more than 300 markets and 250,000 companies spanning 40 global offices.

“This prestigious award is particularly significant to Semprus BioSciences because of Frost & Sullivan’s rigorous and unbiased selection process,” said Chief Executive Officer David L. Lucchino. “We are honored to be recognized for our accomplishments in adopting surface functionalization technology to address medical device safety.”

The Semprus Platform is a single-surface modification that is designed to reduce the attachment of bacteria, fungus, platelets and blood proteins to a device.

“We have recognized Semprus BioSciences with this award because our independent, third party research confirms that Semprus’ unique technology platform is able to adapt to diverse substrates such as polyurethane, silicone and titanium,” explained Frost & Sullivan Research Analyst Prasanna Vadhana, “thus paving the way for next generation products with improved clinical benefits across the medical spectrum.”

Lucchino will accept the award on behalf of Semprus BioSciences at Frost & Sullivan’s 2011 Excellence in Medical Technologies & Life Sciences awards banquet on March 15, 2011, in San Francisco, CA.

In December 2010, Semprus BioSciences completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. This funding adds to an $8 million Series A financing round in 2008 that was co-led by 5AM Ventures and Pangaea Ventures, as well as $2.5 million in seed capital raised. Semprus BioSciences has secured global licenses from the Massachusetts Institute of Technology (MIT) and the University of Washington. The company also holds numerous intellectual property filings and grants from the Department of Defense, the National Institutes of Health (NIH) and the National Science Foundation (NSF), for a total of $2.5 million in grant funding since 2008.

* Journal of Wound Care, February 2010 (Wilcott et al.), Chronic Wounds and the Medical Biofilm Paradigm.

About Semprus BioSciences
Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. Our innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Our current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device.
Click here for the Semprus BioSciences web site.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.